Table 5. Correlation of various factors associated with survival in patients suffering from cerebral mucormycosis (n=58).

BMI, body mass index; ICA, internal carotid artery; ABLC, amphotericin B-lipid complex.

	Survivors (N=37)	Non-survivors (N=21)	p-Value (chi-square test)
Demographics
Age	49.51±12.48 years	52.86±9.25 years
Occupation
Farmer/florist	12	8	0.67
Average BMI	24.78±4.04	22.87±3.46
Smoking/tobacco	19	8	0.33
Diabetes mellitus
Pre-COVID	16	9	0.98
Post-COVID (total)	31	18	0.85
COVID history	35	20	0.92
Hospitalization history	16	9	0.98
Drug treatment received	34	17	0.22
Steroids	24	13	0.82
Time lag between COVID and mucormycosis	18.69±9.59 days	17.63±7.41 days
Neural symptom is seen in	20	12	0.82
Time lag between the onset of mucormycosis and the first neural symptom	22.75±18.15 days	19.46±14.13 days
Radiological findings
ICA thrombosis	9	4	0.64
Cavernous-sinus thrombosis	14	4	0.13
Meningitis	9	3	0.36
Acute infarcts	9	14	0.0015 (significant)
Surgical intervention	35	14	0.004 (significant)
Convention amphotericin	33	20	0.43
Liposomal amphotericin	22	9	0.22
ABLC	4	1	0.43
Retrobulbar amphotericin	7	0	0.03 (significant)
Posaconazole	34	11	0.0005 (significant)